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A B S T R A C T
Aim: Migraine is a neurological debilitating disorder. Previous studies have shown that cannabinoid receptor
agonists have analgesic effects in various models of pain. In this study, therefore, we investigated anti-noci-
ceptive effects of WIN 55,212-2, and the role of either CB1 or CB2 receptors in nitroglycerine (NTG)-induced
animal model of migraine.
Methods: The present study was conducted on both male and female rats receiving NTG (10mg/kg, i.p.) to
induce acute (single dose of NTG) and chronic (repetitive doses of NTG) models of migraine. Additionally, three
groups received WIN 55,212-2 (0.33, 1, 3mg/kg, i.p.) 45min before behavioral tests. Additionally, AM251 and
AM630 (CB1 and CB2 receptor antagonist, respectively, 1mg/kg, i.p.) were used to evaluate the possible in-
volvement of CB1 and CB2 receptors during the protective effects of WIN 55,212-2.
Key findings: We found that NTG (10mg/kg, i.p.) in both acute and chronic models increased sensitivity to pain.
In acute model, we found that WIN 55,212-2 (almost high doses) decreases the level of pain mainly through CB1
receptor due to CB1 antagonist abrogates its protective effects, however, in formalin test CB2 receptors also had
crucial roles in both phases at 3mg/kg of WIN 55,212-2. In chronic model, WIN 55,212-2 (0.33, 1 and 3mg/kg)
significantly attenuated NTG-induced hyperalgesia through both CB1 and CB2 receptors.
Significance: Our data supported the argument that activation of CB1 and CB2 receptors by WIN 55,212-2 may be
considered a new medication for migraine, however in lack of each receptor leads to different responses from
deletion to the reduction of analgesic effects.
1. Introduction
Migraine is considered one of the most common disorders seen in
people with chronic disability [1]. Despite dramatic increases in the
incidence of migraine, our knowledge about its pathophysiology is in-
complete and in many patients, despite the presence of multiple med-
icines, there is found no adequate healing response [1]. Although the
pathophysiology of migraine is difficult to describe, there is a general
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consensus that the main underlying mechanism of migraine attacks are
neurogenic inflammation in dura matter due to activation of the tri-
geminovascular system [2].
One of the most studied human's models of a migraine is designed
by administration of the excessive levels of nitroglycerin (NTG) [3]. In
experimental models, it has been shown that NTG is able to induce
inflammation and also activate the trigeminovascular system [4,5],
which anti-migraine medicines such as sumatriptan can attenuate NTG-
induced allodynia [6]. Therefore, NTG-induced allodynia could be
considered a reliable animal model for investigation of proper treat-
ments for migraine [1,7].
Today, it is believed that cannabinoid (CB) receptors play important
roles in regulating the nociception, control of psychomotor, memory
function, neuroendocrine regulation, motion control, appetite regula-
tion, and vomiting [8–11]. Moreover, several studies reported the ser-
ious role of the endocannabinoid system in the regulation of migraine
pathophysiological mechanisms, that any disruption in this system may
develop the incidence and pain intensity of migraine [11]. Further-
more, several lines of evidences have documented that either the acti-
vation of each endocannabinoids system by either cannabinoid type one
or two receptors (CB1 or CB2, respectively) agonist, or the inhibition of
enzymes involving in degradations of endocannabinoids such as fatty
acid amide hydrolase (FAAH), contribute to an anti-nociception effect
in the NTG-induced pain model of migraine at the periphery, spinal,
and supra-spinal levels, as well as in the processing of pain information
[12–15].
On this basis, the present study was designed to examine the ther-
apeutic effects of WIN 55,212-2, a non-selective cannabinoid receptor
agonist, and the contribution of either CB1 or CB2 receptors in both
NTG-induced acute and chronic models of migraine in rat.
2. Materials and methods
2.1. Experimental animal
In the present study, we used both male and female rats weighing
220–260 g that purchased from Razi Institute, Iran; although previous
studies have reported that there were no differences between male and
female in NTG-induced animal model of migraine [16–18]. Rats were
randomly divided into groups by six animals of each gender (n=12/
group). Animals were housed in a 12/12 h light/dark cycle. Food and
water were available ad libitum. Experiments were conducted between
09.00 and 14.00 at ambient temperature (22–25 °C). Noteworthy, all
rats were acclimatized to the test chamber before starting [19]. All
experiments were approved by the ethical committee of Kashan Uni-
versity of Medical Sciences (Grant No. 94101).
2.2. Drugs administration
A stock of 5mg/ml NTG (dissolved in 30% alcohol, 30% propylene
glycol, and water) was purchased from Caspian Tamin®, Tehran, Iran,
which freshly diluted in 0.9% w/v NaCl solution (saline) to a con-
centration of 1m/ml [20,21]. NTG (10mg/kg) was administered in-
traperitoneally (i.p.) 2 h before nociceptive tests. WIN 55,212-2,
AM251, and AM630 were obtained from Santa Cruz Biotechnology Inc.
(Santa Cruz, CA, USA), and dissolved in a solution containing 5% v/v
DMSO and 0.9% v/v NaCl solution. WIN 55,212-2 was administered
45min before nociceptive tests, which in the antagonist group AM251/
AM630 also injected 15min before WIN 55,212-2 [22].
2.3. Experimental procedures
In the present study, we evaluated the effect of WIN 55,212-2 in
both acute and chronic models and in the presence and absence of ei-
ther CB1 (AM-251) or CB2 (AM-630) receptor antagonists as follows.
2.3.1. Acute model
In this set of experiments, the protective effects of WIN 55,212-2
were investigated against NTG-induced acute animal model of mi-
graine, which summarized in Fig. 1B.
Protocol 1 was done to induce the animal model of migraine using
NTG (10mg/kg, i.p.) administration and evaluation the effects of
medication WIN 55,212-2 (0.33, 1 and 3mg/kg) on the NTG-induced
hyperalgesia. Noteworthy, previous studies have indicated that there
are no differences between saline (0.9% NaCl) and the solution dis-
solving the NTG (6% alcohol, 6% propylene glycol and 0.9% saline)
[16–18].
• Control (i.p.): injection of saline 2 h before nociceptive tests
[16–18].• Vehicle (i.p.): injection of saline and DMSO 2 h before nociceptive
tests• NTG (i.p.): injection of NTG (10mg/kg) and then the vehicle of WIN
55,212-2, 2 h and 45min before nociceptive tests, respectively,
[5,20,23]• NTG+WIN 55,212-2 (i.p): injection of NTG (10mg/kg) and then
different doses of WIN 55,212-2 (0.33, 1 and 3mg/kg), 2 h and
45min before nociceptive tests, respectively, [24].
Protocol 2 was carried out to evaluate the role of CB1 receptor in
the protective effect of WIN 55,212-2 in animal model of migraine
using NTG (10mg/kg, i.p.) administration.
• NTG+AM251(i.p.): injection of NTG (10mg/kg), and then
AM251(1mg/kg), two and 1 h before nociceptive tests, respectively,
[25,26].• NTG+AM251+WIN 55,212-2 (i.p.): injection of NTG (10mg/kg),
AM251 (1mg/kg), two and 1 h, respectively, as well as WIN 55,212-
2 (3mg/kg) 45min before nociceptive tests.
Protocol 3 was also carried out to evaluate the possible role of CB2
receptors on the protective effect of WIN 55,212-2 on the animal model
of migraine using NTG (10mg/kg, i.p.) administration.
• NTG+AM630(i.p.): injection of NTG (10mg/kg), and then
AM630(1mg/kg), two and 1 h before nociceptive tests, respectively,
[10].• NTG+AM630+WIN 55,212-2 (i.p.): injection of NTG (10mg/kg),
AM630 (1mg/kg), two and 1 h, respectively, as well as WIN 55,212-
2 (3mg/kg) 45min before nociceptive tests.
2.3.2. Chronic model
In this model, we evaluated the protective effects of WIN 55,212-2
against the chronic animal model of NTG-induced migraine. For this
aim, NTG (10mg/kg, i.p.) or vehicle was administrated every other day
for 9 days. On the tenth day, all nociceptive tests were done at two
steps, first before the intervention (30min before NTG administration)
and after the intervention (2 h after NTG administration). Noteworthy,
previous studies have also shown that there are no differences between
saline (0.9% NaCl) and the solution dissolving the NTG (6% alcohol, 6%
propylene glycol and 0.9% saline) [16–18]. For formalin test, all no-
ciceptive tests were only performed after the intervention (2 h after
NTG administration). The protocol was summarized in Fig. 1C.
Protocol 1 was done to induce the animal model of migraine using
NTG (10mg/kg, i.p.) administration and also evaluate the protective
effects of WIN 55,212-2 (0.33, 1 and 3mg/kg) on NTG-induced hy-
peralgesia.
• Control (i.p.): injection of saline 2 h before nociceptive tests
[16–18].• Vehicle (i.p.): injection of saline and DMSO 2 h before nociceptive
tests
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• NTG (i.p.): injection of NTG (10mg/kg) and then the vehicle of WIN
55,212-2, 2 h and 45min before nociceptive tests, respectively,
[5,20,23]• NTG+WIN 55,212-2 (i.p): injection of NTG (10mg/kg) and then
different doses of WIN 55,212-2 (0.33, 1 and 3mg/kg), 2 h and
45min before nociceptive tests, respectively, [24].
Protocol 2 was carried out to evaluate the role of CB1 receptor on
the protective effect of WIN 55,212-2 in the animal model of migraine
using NTG (10mg/kg, i.p.) administration.
• NTG+AM251(i.p.): injection of NTG (10mg/kg), and then
AM251(1mg/kg), two and 1 h before nociceptive tests, respectively,
[25,26].• NTG+AM251+WIN 55,212-2 (i.p.): injection of NTG (10mg/kg),
AM251 (1mg/kg), two and 1 h, respectively, as well as WIN 55,212-
2 (0.33, 1 and 3mg/kg) 45min before nociceptive tests.
Protocol 3 was also carried out to evaluate the possible role of CB2
receptors on the protective effect of WIN 55,212-2 in the animal model
of migraine using NTG (10mg/kg, i.p.) administration.
• NTG+AM630(i.p.): injection of NTG (10mg/kg), and then
AM630(1mg/kg), two and 1 h before nociceptive tests, respectively,
[10].• NTG+AM630+WIN 55,212-2 (i.p.): injection of NTG (10mg/kg),
AM630(1mg/kg), two and 1 h, respectively, as well as WIN 55,212-
2 (0.33, 1 and 3mg/kg) 45min before nociceptive tests.
2.4. Tail flick test
To assess thermal nociceptive thresholds, the latency of reflex tail
withdrawal (tail flick test) to remove the tail was carried out with a tail
flick test instrument (Ugo Basile, Italy), which equipped with an auto-
matic interrupter radiant heat. Before the assessments, the animal was
gently restrained and placed on the tail-flick apparatus to be habituated
for the following procedure. Radiant heat was focused on 4–7 cm from
the tail distal end and latency from onset of stimulation to withdrawal
of the tail was recorded. Tail flick latency for each rat was calculated as
the average of three consecutive measurements in 5-min intervals. Cut-
Fig. 1. Chemicals structure (A), and acute (B) and chronic (C) experimental outlines.
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Off limit time for each measurement was set as 20 s to avoid tissue
damage [27,28]. For each animal, the tail flick latency was calculated
as the average of three separate determinations taken with at least
2min between each trial.
2.5. Radiant heat plantar test (thermal allodynia)
To assess thermal nociceptive thresholds, the latency of paw with-
drawal was carried out with a radiant heat plantar test instrument (Ugo
Basile, Italy), which equipped with an automatic interrupter radiant
heat. After the acclimatization period, the radiant heat light source was
emitted on the plantar surface of the hind paw. The time required for
the animal to withdraw the paw was measured as paw withdrawal la-
tency, however, a cut-off of 25 s was considered to prevent tissue injury.
For each animal, the withdrawal latency was reported as the average of
three separate determinations, taken with at least 2min between each
trial [20,29].
2.6. Von Frey filament test (mechanical allodynia)
For assessing the mechanical nociceptive thresholds, the animal was
placed in a comfortable position within a Plexiglas box with mesh
flooring. After cessation of exploratory behavior, the plantar surface of
the animal hind paw was stimulated with the series of von Frey fila-
ments (bending force ranging from 8 to 300 g). A response was de-
termined as lifting or shaking of the paw upon stimulation. Each fila-
ment was applied three consecutive times on the hind paw as long as
either the mouse withdrew its paw or the fiber was bent. The with-
drawal threshold was considered the lighter filament of evoking at least
two withdrawal responses during three consecutive applications with
the same filament. Each filament was applied for approximately 1 s and
the interstimulus interval was also approximately 5–10 s [6,30].
2.7. Formalin test
In this experiment, rats were investigated with formalin for the
evaluation of inflammatory tonic pain. Each animal was placed in a
Plexiglas observation chamber (30× 30×30 cm) with a mirror (an-
gled at 45°) positioned to permit observation of the animal's paws. 50 μl
of 5% formalin was injected subcutaneously into the center of the
plantar surface of a hind paw with a 30-gauge needle. The length of
time in which the animal flinches and shakes or licked the injected paw
were considered during the first 5min of the post-injection period
(phase 1) and then 20min after formalin injection for the 10-min period
(phase 2). The first phase of the response to formalin is considered the
result of chemical activation of nociceptors, whereas the second phase
reflected the inflammatory reaction and central processing [14,31].
2.8. Statistical analysis
The obtained results were expressed as the mean ± SEM. Following
the passing of the normal test Kolmogorov–Smirnov's, statistical ana-
lysis was performed by using one-way or two-way ANOVA test for acute
or chronic models, respectively, and followed by Dunnett's post-test;
using GraphPad Prism 6.0 software (San Diego, CA, USA). Data were
considered statistically significant when a p < 0.05 was achieved. F
values were reported in Table 1. The data and statistical analysis
comply with the recommendations on experimental design, analysis
[32] and data sharing and presentation in preclinical pharmacology
[33,34].
3. Results
3.1. The effects of WIN 55,212-2 on NTG-induced acute model of migraine
As illustrated in Fig. 2, acute administration of NTG (10mg/kg)
significantly decreased the levels of tail flick latency (Fig. 2A,
p < 0.001), and paw withdrawal latency (Fig. 2B, p < 0.001) and
threshold (Fig. 2C, p < 0.001), but markedly increased the levels of
paw licking time in both first (Fig. 2D, p < 0.001) and second (Fig. 1E,
p < 0.01) phases of formalin test compared to the control group. In
contrast, treatment with WIN 55,212-2 notably improved the levels of
tail flick latency (Fig. 2A, 1 and 3 mg/kg, p < 0.001 for both cases),
and paw withdrawal latency (Fig. 2B, 3mg/kg, p < 0.001) and
threshold (Fig. 2C, 0.33, 1 and 3mg/kg, p < 0.001 for all cases), but
markedly attenuated the levels of paw licking time in both first (Fig. 2D,
0.33, 1 and 3mg/kg, p < 0.001 for all cases) and second (Fig. 2E,
3mg/kg, p < 0.01) phases of formalin test compared to the NTG re-
ceiving group.
In the presence of CB1 receptor antagonist AM251 (1mg/kg) and
NTG (10mg/kg), all effects of WIN 55,212-2 were significantly de-
creased in comparison to the absence of AM251 (Fig. 2A–E, p < 0.001,
for all cases), however, the protective and significant effects were ob-
served for both phases of formalin test (Fig. 2A–E, p < 0.001 for both
cases). In the other hand, our record showed that adding the CB2 re-
ceptor antagonist AM630 (1mg/kg) to WIN 55,212-2 (3mg/kg) did not
alter its protective effects against NTG-induced hyperalgesia on the tail
flick and paw withdrawal latencies (Figs. 1, 2A and B). Although this
combination significantly reduced the protective effects of WIN 55,212-
2 (3mg/kg) on tests of paw withdrawal threshold (Fig. 2C, p < 0.001)
and both phases of formalin (Fig. 2D and E, p < 0.001 for both cases),
the combination of AM630 (1mg/kg) to WIN 55,212-2 (3mg/kg)
markedly enhanced the level of paw withdrawal threshold (Fig. 2C,
p < 0.001), and reduced the levels of both first (Fig. 2D, p < 0.001)
and second phases of formalin test (Fig. 2E, p < 0.01) compared to the
NTG-induced migraine group.
3.2. The effects of WIN 55,212-2 on NTG-induced chronic model of
migraine
Repeated administration of NTG (10mg/kg), every other day for
9 days and day 10, notably reduced the levels of tail flick and paw
Table 1
Summary of ANOVA test analysis.
Model Test Types of ANOVA test F value (DFn, DFd) P value
Acute Tail Flick One-way F (9, 110)= 14.16 P < 0.0001
Radiant heat plantar test One-way F (9, 110)= 23.35 P < 0.0001
Von Frey filament test One-way F (9, 110)= 26.59 P < 0.0001
Formalin test (1st phase) One-way F (9, 110)= 29.51 P < 0.0001
Formalin test (2nd phase) One-way F (9, 110)= 18.37 P < 0.0001
Chronic Tail Flick Two-way F (13, 308)= 22.63 P < 0.0001
Radiant heat plantar test Two-way F (13, 308)= 22.28 P < 0.0001
Von Frey filament test Two-way F (13, 308)= 29.31 P < 0.0001
Formalin test (1st phase) One-way F (13, 154)= 17.66 P < 0.0001
Formalin test (2nd phase) One-way F (13, 154)= 15.48 P < 0.0001
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Fig. 2. The effects of different doses of WIN 55,212-2 on the acute model of nitroglycerin (NTG)-induced (10mg/kg, i.p.) thermal allodynia [the tail flick (A) and paw
withdrawal latencies (B)] and mechanical allodynia [the paw withdrawal threshold, (C)] tests as well as first (D) and second (E) phases of formalin test in the
presence or absence of either CB1 or CB2 receptor antagonist (AM251 or AM630, respectively), (n=12). Data were shown as mean ± SEM. Following the passing of
the normal test Kolmogorov–Smirnov's, statistical analysis was performed by using one-way ANOVA test, and followed by Dunnett's post-test; using GraphPad Prism
6.0 software (San Diego, CA, USA). + shows a comparison between the control or vehicle group with the NTG group, ++: p < 0.01, +++: p < 0.001; * shows a
comparison between WIN 55,212-2 treated groups in the presence or absence of the CB1 or CB2 receptor antagonist to the respected NTG group, **: p < 0.01 and
***: p < 0.001; x indicates a comparison between the equal doses of WIN 55,212-2 groups in the presence or absence of either CB1 or CB2 receptor antagonist, xxx:
p < 0.001.
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withdrawal latencies as well as the level of paw withdrawal threshold
compared to the control group (Fig. 3A, B and C, p < 0.001 for all
cases). Furthermore, NTG (10mg/kg) significantly increased the dura-
tion of paw licking time of formalin test in both first (Fig. 4A,
p < 0.001) and second (Fig. 4B, p < 0.001) phases in comparison to
the control group. In contrary, our result indicated that treatment with
WIN 55,212-2 75min after last dose of NTG on day 10, significantly and
dose-dependently elevated the levels of tail flick (Fig. 3A, 1 and 3 mg/
kg, p < 0.001 for both cases) and paw withdrawal (Fig. 3B, 1 and 3
mg/kg, p < 0.001 for both cases) latencies as well as the level of paw
withdrawal threshold (Fig. 3C, 0.33, 1 and 3mg/kg, p < 0.001 for all
cases) in comparison to the NTG-induce migraine group. Additionally,
WIN 55,212-2 (1 and 3mg/kg) markedly abrogated the duration of
formalin-induced paw licking in both phases compared to the NTG-in-
duce migraine group (Fig. 4A and B, p < 0.001 for all cases).
In the presence of CB1 receptor antagonist AM251 (1mg/kg), the
effects of different doses of WIN 55,212-2 were significantly attenuated
on the levels of tail flick (Fig. 3A, 1 and 3 mg/kg, p < 0.001 for both
cases) and paw withdrawal (Fig. 3B, 1 and 3 mg/kg, p < 0.001 for
both cases) latencies as well as the level of paw withdrawal threshold
(Fig. 3C, 0.33mg/kg, p < 0.05, 1mg/kg, p < 0.001, and 3mg/kg,
p < 0.001), in comparison to the equal dose of WIN 55,212-2 without
AM251 against NTG-induced migraine group. We also found that the
use of AM251 (1mg/kg) 15min before WIN 55,212-2, led to significant
increases in the duration of formalin-induced paw licking in both first
(Fig. 4A, 1 and 3 mg/kg, p < 0.001 for both cases) and second (Fig. 4B,
1 mg/kg, p < 0.001, and 3mg/kg, p < 0.001) phases, compared to
the absence of AM251 in the present of NTG-induced migraine model.
However, in the present of AM251 (1mg/kg), WIN 55,212-2 sig-
nificantly increased the levels of tail flick (Fig. 3A, 3 mg/kg,
p < 0.001) and paw withdrawal (Fig. 3B, 3 mg/kg, p < 0.001) la-
tencies, and paw withdrawal threshold (Fig. 3C, 1 and 3 mg/kg,
p < 0.001 for both cases), while notably decreased the duration of paw
licking (Fig. 4B, 3 mg/kg, p < 0.01) at the second phase of formalin
tests, compared to the NTG-induced migraine group.
In the presence of CB2 receptor antagonist AM630 (1mg/kg), the
effects of high dose of WIN 55,212-2 (3mg/kg) was markedly subsided
on the levels of tail flick (Fig. 3A, p < 0.001) and paw withdrawal
(Fig. 3B, p < 0.001) latencies, and paw withdrawal threshold (Fig. 3C,
p < 0.001), as well as the duration of paw licking in both first (Fig. 4A,
p < 0.05) and second (Fig. 4B, p < 0.001) phases of formalin test,
compared to the equal dose of WIN 55,212-2 in the presence of NTG-
induced migraine group. Nevertheless, in the present of AM630 (1mg/
kg), our records elucidated that WIN 55,212-2 significantly increased
the levels of tail flick (Fig. 3A, 1 and 3 mg/kg, p < 0.001 for both
cases) and paw withdrawal (Fig. 3B, 1 and 3 mg/kg, p < 0.001 for
both cases) latencies as well as the level of paw withdrawal threshold
(Fig. 3C, 0.33, 1 and 3mg/kg, p < 0.001 for all cases) in comparison to
the NTG-induce migraine group. Additionally, WIN 55,212-2 (1 and
3mg/kg) markedly abrogated the duration of formalin-induced paw
licking in both first (Fig. 4A, p < 0.01 for both cases) and second
(Fig. 4B, p < 0.001 for both cases) phases compared to the NTG-induce
migraine group.
4. Discussion
To the best of our knowledge, this is the first mechanistic study
regarding the protective effects of WIN 55,212-2 as non-selective CB1/
CB2 receptor agonist against NTG-induced acute and chronic animal
models of migraine. As results, we found that the administration of NTG
(10mg/kg, i.p.) in both acute and chronic models increased sensitivity
to pain in different models of pain. In acute model, we found that the
use of WIN 55,212-2 (almost high doses) decreases different models of
pain mainly through CB1 receptors due to CB1 antagonist abrogates its
protective effects; however, in formalin test CB2 receptors also had a
crucial role in both phases at 3mg/kg of WIN 55,212-2. In the chronic
model of migraine, WIN 55,212-2 also significantly attenuated NTG-
induced hyperalgesia through both CB1 and CB2 receptors which the
CB2 receptor showed a prominent role as well as CB1 receptor at the
high dose of WIN 55,212-2.
For investigation of new medications for treatment of migraine,
there are several experimental models which one of the most commonly
used model is NTG-induced migraine pain, since it induces a condition
of hyperalgesia in the rat and is associated with the activation of both
spinal cord and brain structures involving in nociception [17,35,36]. In
fact, nitric oxide (NO) donor compounds such as NTG potentiate re-
sponses of dorsal horn to afferent stimulation, intensify the sub-
population of trigeminal afferents innervating the dura matter, and also
have an important role in inflammatory hyperalgesia [16,20,35,36].
Moreover, important neuronal activity and regulatory roles of NO
cannot be ignored in the peripheral, spinal, and supra-spinal levels, as
well as in the processing of pain information [20,35,36]. In this regard,
in the present study, we used NTG (10mg/kg, i.p.) for the induction of
acute and chronic migraine models in both male and female rats. In
agreement to previous reports, we found that there is no difference
between male and female nociceptive test responses by NTG
[16,17,35]. Based on the pieces of evidence, NTG leads to headaches in
normal people and also stimulates a migraine without aura. Moreover,
NTG-induced hyperalgesia is associated with the development of sen-
sory hypersensitivity with a migraine. Contextually, the acute admin-
istration of NTG led to mechanical and thermal hyperalgesia, which
were improved using an anti-migraine medication sumatriptan [35].
Furthermore, it has been indicated that the administration of NTG
causes hypersensitivity to light and increases meningeal blood flow in
mice [35]. Our results of induction of migraine models may be sup-
ported by these studies.
In the present study, WIN 55,212-2 reversed the effects of NTG-
induced hyperalgesia in a dose-dependent fashion in both models of
acute and chronic migraine. Using the von Frey filaments, we demon-
strated that the use of WIN 55,212-2 (0.33, 1 and 3mg/kg) enhances
the paw withdrawal threshold against both acute and chronic models of
NTG-induced migraine in a dose-dependent manner. It has been already
stated that the tail flick assay evaluates the pain threshold at the spinal
level, however upper areas such as the brainstem and cortical regions
are able to modify its reflexing responses [37]. Besides, we also per-
formed the radiant heat plantar test (Hargreaves test) to have a better
insight onto the distinction between the effects of WIN 55,212-2 on the
spinal and supraspinal levels, because of this test requires supraspinal
and integration of higher structures to indicate reflexes [29,37]. In this
regard, we used both the tail flick assay and radiant heat plantar test to
examine the analgesic effect of WIN 55,212-2 at spinal and supraspinal
levels. In acute model, we found that middle dose of WIN 55,212-2
(1mg/kg) reduces the thermal hyperalgesia at the spinal level, while
according to the finding from radiant heat plantar test, high dose of
WIN 55,212-2 (3mg/kg) may act through supraspinal structures to
reduce the pain. In fact, in the present study, we administrated WIN
55,212-2 systematically (i.p.) and carried out neither specific suprasp-
inal tests nor the cephalic administration study, therefore, we cannot
exactly distinguish between spinal and supraspinal sites involving in its
analgesic effects. As regards, there are many studies implication that
cannabinoid ligands exert their analgesic effects through acting at both
spinal and supraspinal sites as well as in the periphery [11,38]. In one
study, Ebrahimzadeh and coworker indicated that the administration of
WIN 55,212-2 in the nucleus cuneiformis (NCF), the supraspinal neu-
roanatomical regions involving the modulation of pain, makes dose-
dependent analgesic effects against acute and inflammatory pain
models (tail-flick and formalin tests) [39]. Indeed, this study also in-
dicates supraspinal analgesic effects of WIN 55,212-2. Moreover, spin-
ally administration of WIN 55,212-2 diminishes thermal hyperalgesia in
diabetic rats but this effect is not more effective rather than the sys-
tematic administration [40]. Additionally, it has been showed that a
systemic administration of cannabinoid ligand WIN55,212-2 is effective
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in decreasing the mechanical allodynia in different animal models of
pain [41,42].
Interestingly, in the chronic model, we observed that both middle
and high doses of WIN 55,212-2 (1 and 3mg/kg, respectively) also
produce obvious analgesic effects against chronic administration of
NTG at both spinal and supraspinal levels. There are several studies
notion that either the repetitive or the prolonged pain stimulation, for
example, following traumatic injury or an inflammatory process, the
expression levels of cannabinoid receptors and of endocannabinoids
will be increased both centrally and peripherally, thereby helping to
reduction of the pain intensity [11,43–46]. Hence, the effects of the
middle dose of WIN 55,212-2 may be explainable via the over-
expression of CB receptors, although we performed no investigation in
this case as one of this study limitation.
There is some evidence that the stimulation of sensorial areas is not
considered supraspinal distribution, which may limit the use of the
findings for treatment of migraine [14,47], thereby the formalin test
was performed in the present study. Previous studies indicated that
plantar injection of formalin in rats leads to significant changes in
calcitonin gene-related peptide (CGRP) levels in the superficial laminae
I and II, ipsilateral to the injection side and also in the nucleus trige-
minalis caudalis (NTC) and that systemic NTG administration similarly
causes a reduction in the level of CGRP-immunoreactivity in the NTC,
but not in the lumbar dorsal horns [47,48]. In consistent with these
studies, in our experiment, we also found that either the acute or the
chronic administration of NTG significantly potentiates both phases of
the formalin test. Indeed, NTG may induce a direct hyperalgesic effect
via formation of NO and liberation of CGRP in the NTC [49], or in-
directly via activation of NOS at the meningeal level as a consequence
of sensitization of the trigeminovascular system. Collectively, NTG-
potentiated formalin test can be considered a relevant model for in-
vestigating migraine circuitry, which it has been shown that formalin
injection in the paw elevates the expression level of Fos in NTC, and
other brainstem areas such as locus coeruleus involving in the mod-
ulation of migraine pain [49,50].
Hopefully, it was observed that WIN 55,212-2 attenuates the first
phase of formalin at all doses, while the high dose had a significant
effect in the second inflammatory phase of formalin test in the acute
model. In contrary, both middle and high doses of WIN 55,212-2 had a
notable analgesic effect in both phases of formalin test in the chronic
model. Likely, different exposures to painful stimuli increase the sen-
sitivity to the pain also the overexpression of endocannabinoid re-
ceptors and ligands, therefore WIN 55,212-2 (1 and 3mg/kg) exerts a
putative analgesic effect at the lower dose. However, it needs further
investigations in order for this to be confirmed, our findings were in
agreement with other studies that indicate the contribution of activa-
tion of cannabinoid receptors in reduction of inflammatory responses
such as formalin test in NTG-induced model of migraine [12,14,51].
There are several reports regarding the pivotal role of cannabinoids
in regulation of many functions in the body, including modulation of
Fig. 3. The effects of different doses of WIN 55,212-2 on the chronic model of nitroglycerin (NTG)-induced (10mg/kg, i.p.) thermal allodynia [the tail flick (A) and
paw withdrawal latencies (B)] and mechanical allodynia [the paw withdrawal threshold, (C)] tests in the presence or absence of either CB1 or CB2 receptor antagonist
(AM251 or AM 630, respectively), (n= 12). Following the passing of the normal test Kolmogorov–Smirnov's, statistical analysis was performed by using two-way
ANOVA test, and followed by Dunnett's post-test; using GraphPad Prism 6.0 software (San Diego, CA, USA). + shows a comparison between the control or vehicle
group with the NTG group, ++: p < 0.01, +++: p < 0.001; * shows a comparison between WIN 55,212-2 treated groups in the presence or absence of the CB1 or
CB2 receptor antagonist to the respected NTG group, **: p < 0.01 and ***: p < 0.001; x indicates a comparison between the equal doses of WIN 55,212-2 groups in
the presence or absence of either CB1 or CB2 receptor antagonist, xxx: p < 0.001.
Fig. 3. (continued)
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pain in peripheral, spinal, and supraspinal nociception. The CB1 re-
ceptor is mainly distributed throughout the CNS and PNS, which
mediates psychoactivity, pain regulation, memory processing and
motor control. The presynaptic CB1 heteroreceptor modulates the re-
lease of neurotransmitter and neuropeptide and prevents synaptic
transmission by the activation of inwardly rectifying potassium chan-
nels, and in the inhibition of voltage-sensitive calcium channels
[9,14,46,52]. The CB2 receptor is found predominantly at the periphery
and in the immune system cells. Activation of CB2 receptors lead to the
inhibition of cytokine/chemokine release and resolution of chronic
inflammatory processes and modulate chronic pain. Additionally, it has
been shown that the CB2 activators lead to the release of β-endorphin
acting at μ opioid receptors on peripheral sensory neurons to inhibit
nociception [9,14,46,52]. Although the density of CB2 receptors is at
low levels in the CNS and PNS, they may be overexpressed in microglia
following the inflammation and after peripheral nerve damage
[9,14,46]. Moreover, it is worth mentioning that CB1/CB2 receptors
may reduce pain through interaction with other receptors and pro-
viding hetero receptors including, the putative non-CB1/CB2 cannabi-
noid G protein-coupled receptor (GPCR) 55 (GPR55) or GPR18, opioid
receptors, serotonin (5-HT) receptors, nuclear receptors (peroxisome
proliferator-activated receptors, PPARs), cys loop ligand-gated ion
channels and transient receptor potential (TRP) channels [9,14,46,52].
Therefore, to have a better understanding onto the involved me-
chanisms during the protective effects of WIN 55,212-2 against NTG-
induced model of acute and chronic pain, we also evaluated its effect in
the presence of either CB1 or CB2 receptors antagonists. Interestingly,
we discovered that the CB1 receptor has a highlighted role in the pain
modulation of WIN 55,212-2 in the acute model of migraine due to the
use of CB1 antagonist AM251 completely reversed its protection in
contrary the use of CB2 antagonist AM630. In a similar way, in the
chronic model, the use of CB1 receptor antagonist significantly lessened
the protective effects of WIN 55,212-2 but not completely since its
protective effects were observed. As another key finding of the present
study, we indicated that WIN 55,212-2 at the dose of 3mg/kg exerted
its significant analgesic effects through CB2 receptors due to the use of
an antagonist reduced the protection, although it was more obvious in
the chronic model. Indeed, it suggests that analgesic effects induced by
WIN 55,212-2 are mediated via both CB1 and CB2 receptors, which in
lack of each receptor leads to a wide response from deletion to the
reduction of analgesic effects. In accordance with our findings,
Akerman et al. examined responses of rats following the dural electric
stimulation and facial activation in the ophthalmic branch of the tri-
geminal nerve and the effect of the cannabinoid receptors agonist and
antagonist. They showed that WIN 55,212-2 inhibits neuronal re-
sponses in type A and C fibers by 25% and 44%, respectively, which
these effects are blocked by the CB1 antagonist but not in the present of
the CB2 antagonist [1]. Furthermore, Kazemi et al. explained the effects
of the cannabinoid system on the CSD in rats. The CSD plays a major
role in some neurological diseases such as a migraine with aura which is
thought to be equivalent to a migraine in humans. The release of CSD-
like waves in human neocortical tissues causes aura symptoms in mi-
graine patients. It is argued that CSD may be a stimulant to initiate pain
in migraine attacks. Their results indicated that CB1 agonist WIN
55,212-2 significantly inhibited CSD, while the JWH-133 CB2 agonist
had no effects on CSD [53]. These studies may support our finding
regarding the CB1 receptor-mediated effects of WIN 55,212-2. On the
other hand, there are some studies which disagree to the unique role of
CB1 receptors in protective effects of WIN 55,212-2. In one study,
protective effects of WIN 55,212-2 were examined on a murine model
of bone cancer pain to investigate underlying peripheral neural me-
chanisms [54]. Their results demonstrated that activation of either CB1
or CB2 receptors significantly reduced WIN 55,212-2 effects on the
spontaneous activity of C-fiber nociceptors associated with tumor
growth, and responses to mechanical stimulation. In fact, this study
indicates the involvement of peripheral CB1 and CB2 receptors in the
reduction of pain. Furthermore, the antinociceptive effect of intrathecal
administration of WIN 55,212-2 was investigated in a rat bone tumor
pain model [55]. They clarified that both CB1 and CB2 receptors involve
through the antinociceptive effect of WIN 55,212-2 due to the use of
each antagonist significantly provided fewer responses. Indeed, this
study indicates the centrally acting role of either CB1 or CB2 receptors
in addition to the periphery, which they may confirm our findings on
modes of action of WIN 55,212-2 in NTG-induced acute and chronic
models.
There are several limitations regarding the translational data from
38 
Fig. 4. The effects of different doses of WIN 55,212-2 on the chronic model of
nitroglycerin (NTG)-induced (10mg/kg, i.p.) migraine on first (A) and second
(B) phases of formalin test in the presence or absence of the CB1 or CB2 receptor
antagonist (AM251 and AM 630, respectively), (n= 12). Following the passing
of the normal test Kolmogorov–Smirnov's, statistical analysis was performed by
using one-way ANOVA test, and followed by Dunnett's post-test; using
GraphPad Prism 6.0 software (San Diego, CA, USA). + shows a comparison
between the control or vehicle group with the NTG group, ++: p < 0.01, +++:
p < 0.001; * shows a comparison between WIN 55,212-2 treated groups in the
presence or absence of the CB1 or CB2 receptor antagonist to the respected NTG
group, **: p < 0.01 and ***: p < 0.001; x indicates a comparison between the
equal doses of WIN 55,212-2 groups in the presence or absence of the CB1 or
CB2 receptor antagonist, xxx: p < 0.001.
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animal studies of headache to the clinical study. The use of NTG in
rodents may be effectively modeled migraine-like symptoms, even
though doses, type of administrations and the determination of the time
of observation need to be carefully monitored when animal models
based on NTG are aimed for the study of the trigeminovascular system
[56,57]. In fact, the NTG doses in the experimental study are mean-
ingfully more than those seen in the clinical study [58]. It is worth
mentioning that several factors should be taken into consideration to
estimate the in vivo experimental doses especially the pharmacokinetic
of inducing agent including time to maximum effect, rate of metabo-
lism, and body surface area [59]. Therefore, the required effective an-
imal dose may be increased by these underling factors. In addition,
although the administration of NO donors such as glycerol trinitrate
have been demonstrated to provide an animal model of migraine pain
similar to migraineurs, the NTG-induce animal model of migraine does
not reduce the cortical-spreading depression (CSD) and liberate CGPR
in the blood circulation [56,57]. Tactile allodynia is found a common
characteristic of migraine and several methods have been used to ex-
plore and examine this. In animal models, NTG leads to a thermal and
mechanical allodynia that can be reversed using an anti-migraine
medicine sumatriptan [20,56,57,59]. In this model, thermal and me-
chanical nociceptive thresholds are routinely indicated by hind paw
withdrawal, a spread of tactile allodynia to other areas of the body such
as limbs is seen during a migraine attack, and not directly examined the
nociception in the facial region and craniofacial structures, however
[56,57]. Therefore, further preclinical methods of headache should be
taken into account to evaluate the protective effects of WIN 55,212-2 on
the resolution of headache and migraine.
In conclusion, our data supported the argument that activation of
CB1 and CB2 receptors by WIN 55,212-2 may be considered a new
medication for migraine. However, we found that anti-nociceptive ef-
fects of non-selective cannabinoid agonist WIN 55,212-2 are mediated
via both CB1 and CB2 receptors, which in lack of each receptor leads to
different responses from deletion to the reduction of analgesic effects.
Finally, we need more experimental and clinical investigations to
achieve the argument of the efficacy and safety of the non-selective
cannabinoid agonist due to the potential of overuse and psychiatric
effects through CB1 receptor activation, which these may limit their
development for pain treatments.
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